Xenetic Biosciences reports developments tied to its immuno-oncology programs for difficult-to-treat cancers. The company’s DNase technology targets neutrophil extracellular traps, or NETs, with a systemic DNase program being advanced as an adjunctive approach for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Recurring updates include preclinical and translational research, conference presentations, collaborations with institutional and development partners, and studies evaluating DNase I with chemotherapy, immunotherapies and CAR T-cell approaches. Company news also covers periodic financial results, cash resources, equity financing, shareholder voting matters and other governance developments.
Xenetic Biosciences (NASDAQ:XBIO) announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will take place from November 6-10, 2024, in Houston, Texas and virtually.
The presentation details are as follows:
- Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC
- Abstract Number: 765
- Presenter: Reid Bissonnette, Ph.D., Executive Consultant for Translational Research and Development at Xenetic
- Date and Time: Friday, November 8, 2024, 9:00 a.m.-7:00 p.m. CST
- Location: George R. Brown Convention Center -Level 1 -Exhibit Halls AB
Xenetic Biosciences (NASDAQ:XBIO) has entered into a Materials Transfer Agreement with Tokyo Medical University to advance its systemic DNase program. The agreement involves evaluating the effects of human recombinant DNase I (rhDNase I) in combination with chemotherapy for Ewing sarcoma, an aggressive pediatric cancer.
Professor Takuro Nakamura will lead the research using a proprietary immunocompetent preclinical mouse model. This model reflects the characteristics of human Ewing sarcoma and has shown translational relevance. The study aims to assess DNase's ability to reduce neutrophil extracellular traps (NETs) in the tumor microenvironment and enhance chemotherapy efficacy.
Previous clinical studies at Tel Aviv Medical Center demonstrated that NETs formation in Ewing sarcoma tumors is an independent prognostic factor, with higher NETs levels associated with poor prognosis and treatment response.
Xenetic Biosciences (NASDAQ:XBIO), a biopharmaceutical company focusing on innovative immune-oncology technologies for hard-to-treat cancers, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Jim Parslow, the company's Interim CEO and CFO, delivered a presentation at the event. The video webcast of this presentation is now available on the Events page in the Investors section of Xenetic's website (www.XeneticBio.com) and will remain accessible for 90 days.
Xenetic Biosciences (NASDAQ:XBIO) reported its Q2 2024 financial results and provided a business update. Key highlights include:
1. Ongoing preclinical studies with data expected before year-end
2. Focus on demonstrating DNase-based oncology program in clinical proof-of-concept studies
3. Q2 2024 net loss of $1.3 million
4. R&D expenses remained flat at $0.9 million
5. G&A expenses increased by 19.5% to $1.1 million
6. Royalty payments of $0.7 million, an 11.6% increase year-over-year
7. Cash position of $7.3 million at quarter-end
The company remains confident in its DNase-based oncology platform and is advancing towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors.
Xenetic Biosciences has announced the appointment of James F. Parslow as the interim Chief Executive Officer, effective May 16, 2024. Parslow, currently the Chief Financial Officer, will lead the company as it focuses on advancing its immune-oncology technologies. The company aims to drive its pipeline toward a first human clinical study and extend its cash runway. Xenetic is moving forward with its DNase-based oncology program, targeting pancreatic carcinoma and other advanced solid tumors, with preclinical data expected by year-end.
Xenetic Biosciences, Inc. reported its financial results for the first quarter of 2024, highlighting ongoing preclinical studies, advancement of DNase-based oncology program, and ending the quarter with $7.8 million in cash. The net loss for the quarter was approximately $1.2 million, with research & development expenses increasing by 58.6% and general and administrative expenses decreasing by 9.8% compared to the same quarter in 2023.
Summary not available.
Summary not available.
Summary not available.
Summary not available.